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Abstract
Introduction. Prostate cancer is the second most common neoplasm among men both worldwide and in Poland.  
In prostate cancer, bone metastasis is related to a poorer prognosis. A diagnosis of metastatic bone disease is important in 
prostate cancer patients prior to therapy. Prostate specific antigen (PSA) serum value is used both as a screening tool and 
for staging of prostate cancer.  
Aim. To evaluate whether there is a link between symptoms presented by patients, pain in particular, and the presence, 
number and location of bone metastases as assessed by bone scan scintigraphy in concordance with PSA values and Gleason 
scores.  
Material. A group of 186 patients (aged: 68.38±6.16) diagnosed with prostate cancer, from rural and suburban areas of 
Małopolska province, that was directed for bone scan scintigraphy to the Nuclear Medicine Dept, John Paul II Hospital in 
Kraków.  
Methods. Analysis of all laboratory findings (including PSA value) and a biopsy were performed. Then, bone scan scintigraphy 
was done with the use of methylene disphosphonate (MDP) labeled with Tc-99m.  
Results. In patients with a Gleason value ≤7 and a PSA value ≤20 ng/ml, the cutoff value for a negative bone scan with a 
confidence interval of 0.95 was established at a PSA value below 10 ng/ml (p<0.01). Correlations were established between 
PSA value and presence of metastases in bone scan (r=0.45, p=0.05), the number of metastases (r=0.66, p<0.01), and their 
presence in particular body regions.  
Conclusions. The correlation between PSA value and both presence and number of metastases confirms the usefulness of 
bone scan scintigraphy in prostate cancer staging. The cutoff value for negative bone scan with a 95% confidence interval 
was established at PSA = 10 ng/ml.
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INTRODUCTION
Prostate cancer is still the most prevalent type of malignancy 
among males, with an incidence rate of 214 cases per 1000 
men, outnumbering lung and colorectal cancer and, while 
progress has been made towards improved methods of 
therapy, it is still the sixth-leading cause of cancer deaths 
among men (6.1% of total) [1], with an estimated 258,000 
deaths in 2008. Incidence rates based on PSA screening of 
prostate cancer vary by a factor of more than 25 worldwide 
(the highest rates are in Australia/New Zealand (104.2 
per 100,000), western and northern Europe, and North 
America, largely because the practice of prostate specific 
antigen (PSA) testing and subsequent biopsy has become 
widespread in those regions). Mortality rates are generally 
high in predominantly black populations (the Caribbean, 
26.3 per 100,000 and sub-Saharan Africa, 18–19 per 100,000), 
very low in Asia and intermediate in the rest of Europe and 
Oceania (IARC data) [1, 2]
There are three well-established risk factors for developing 
prostate cancer: aging, ethnic origin (black population) and 
genetic predisposition. Clinical and epidemiological data also 
suggest roles for diet, pattern of sexual behavior, excessive 
alcohol consumption, exposure to ultraviolet radiation 
and occupational exposure in rural areas to chemicals and 
pesticides used in agriculture that may also play a role in 
the risk of developing prostate cancer. Patterns of behavior 
reported to have preventive properties include certain diets 
(low-fat diet, use of plant-based fats) and regular physical 
exertion [3].
The choice of most appropriate therapy among patients with 
prostate cancer is based on the proper staging of the disease 
at the time of diagnosis. Clinical staging procedures include 
digital serum PSA measurements, rectal examination, bone 
scan scintigraphy, and, if necessary in the case of enlarged 
adenoma and high probability of metastases other than to 
bone in some patients, computer tomography or magnetic 
resonance imaging studies. Bone is considered the second 
most common site, after lymph nodes, for metastases from 
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prostate cancer. Around 5% to 15% of patients first diagnosed 
with prostate cancer already have bone metastases as well. In 
patients who actually die of prostate cancer, metastases to the 
skeleton are found in more than 80% of patients. Thus proper 
staging and screening for the presence of bone metastases 
have a major impact on both the prognosis and choice of 
treatment for each individual patient [3, 4,5].
Bone scan scintigraphy with the use of Tc-99m-labeled 
methylene diphosphate is superior to all other imaging 
modalities and, thanks to its high accuracy in the detection 
of metastatic bone disease, is considered the most sensitive 
staging method for prostate cancer [2, 4, 5].
One of the routinely used methods in prostate cancer 
staging is prostate gland biopsy. The Gleason grading 
system is used for proper evaluation. Basically, a Gleason 
score is given to prostate cancer based upon its microscopic 
appearance in material obtained via biopsy. Cancers with 
higher Gleason scores tend to be more aggressive and have a 
worse prognosis than those with lesser scores. According to 
current international convention, the Gleason score of cancers 
detected in a prostate biopsy consists of the Gleason grade of 
the dominant (most extensive) carcinoma component plus 
the highest grade detected in other material, regardless of 
its extent. Then the two grades are added together to make 
a total Gleason score. The Gleason grade ranges from 1 to 5 
and the Gleason score from 2 to 10, with 10 indicating the 
worst prognosis [5].
Among published papers on early detection and staging 
of prostate cancer, much stress is placed on the low value of 
baseline bone scan scintigraphy if PSA levels are less than 
10 ng/ml [6], or on the suggestion to avoid bone scintigraphy 
when combined PSA values are less than 10 ng/ml and the 
Gleason score is less than 7 [7, 8]. Other papers suggest 
avoiding bone scan scintigraphy in the case of PSA levels less 
than 15 ng/ml [9]. It has also been stated in current guidelines 
[4] that “skeletal metastasis (M staging) is best assessed 
by bone scan. This may not be indicated in asymptomatic 
patients if the serum PSA level is <20 ng/ml in the presence 
of well-differentiated or moderately differentiated tumors. 
“The cited guidelines are based on well-conducted clinical 
studies, but without randomized clinical trials and have 
recommendation grade B.
However, to the authors’ knowledge, many patients sent to 
undergo a bone scan scintigraphy are asymptomatic, while 
having visible bone metastases.
Toward this end, our aims for the study were:
•	 To evaluate whether there are links between PSA values 
and presence and number and location of bone metastases 
as assessed by bone scan scintigraphy.
•	 To evaluate whether there is a link between Gleason score 
and presence, number and location of bone metastases as 
assessed by bone scan scintigraphy.
•	 To evaluate whether there is a link between symptoms 
presented by patients, pain in particular, and presence, 
number and location of bone metastases as assessed by 
bone scan scintigraphy in concordance with PSA values 
and Gleason score.
MATERIAL AND METHODS
A group of 186 patients (aged: 68.38±6.16) from rural 
and suburban areas of Małopolska province, with newly-
diagnosed, untreated prostate cancer, directed for bone scan 
scintigraphy to the Nuclear Medicine Dept., John Paul II 
Hospital in Kraków from January 2010 to December 2012, 
were included in this study. The average time since diagnosis 
in the studied group was 1.24±1.3 months. For all patients, 
adenocarcinoma had been confirmed by core biopsies 
(obtained from pathology reports, the medical charts of 
each patient, or both) resulting in an average Gleason score 
from biopsy results of 6.49±1.1. Serum PSA determinations 
were obtained within 2 months prior to the bone scan with an 
average value of 20.84±21.12 ng/ml within the studied group.
Following a careful review of their history, all patients 
answered a questionnaire regarding pain localization and 
intensity in regard to general pain and localized pain, using 
the Universal Pain Assessment tool and 10-point scale [10] in 
which 0 equals “no pain” and 10 equals “worst pain possible” 
as well as Activity Tolerance Scale, in which 0 equals “no 
pain” and 10 equals “bedrest required”.
Next, whole-body scintigraphy bone scans were performed 
3 to 4 hours after intravenous injection of 700–840 MBq Tc-
99m methylene diphosphate. All images were obtained using 
a large-field-of-view SIEMENS E.CAM dual-head gamma 
camera equipped with a parallel-hole, Low Energy-High 
Resolution (LEHR) collimator. The bone scans were evaluated 
independently by two nuclear medicine physicians (WS 
and MK) and were interpreted as negative or positive for 
scintigraphic evidence of bone metastases. The presence of 
skeletal metastasis in a bone scan was defined when either 
solitary or multiple asymmetric areas of increased uptake of 
the tracer occurred, excluding tracer accumulations related to 
previous trauma and degenerative bone diseases. All lesions 
suspected of being metastases were counted and evaluated in 
additional studies such as radiographs, CT or MRI performed 
to confirm the presence of bone metastases. Data were also 
compared with each patient’s history, excluding tracer 
accumulations related to previous trauma and degenerative 
bone diseases. Sometimes, in patients with disseminated 
bone metastases, because of substantial uptake of the 
radiotracer in multiple metastatic bone lesions, the kidneys 
were not visualized in the bone scan. This pattern is termed 
“superscan” and is associated with a poor prognosis. Patients 
with “superscan” were excluded from the study. No patient 
was on hormonal therapy at the time of the data acquisition.
The gathered data were used to establish the final 
interpretation of the bone scans. In addition, bone scans 
were divided into areas (skull, spinal column, ribs, pelvis 
and extremities) to match areas previously identified using 
the Universal Pain Assessment questionnaire.
Bone scan findings were confirmed with plain radiographs, 
CT or MRI studies. Pain intensity scores and locations from 
patients’ anamensis, serum PSA levels and Gleason scores 
were correlated with the bone scan findings. Statistical 
comparisons were made using a student t-test or a chi-
squared test; correlations were established using Pearson’s 
test. Values of p< 0.05 were considered significant.
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RESULTS
The average BMI in studied group was 26.13±2.87 (min.: 
21.38, max. 36.29, median: 25.79). Gleason score and PSA 
values for the studied group are shown in Table 1 and Fig. 1.
Table 1. Characteristics of the study group
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Figure 1. PSA value in studied group
A positive bone scan result for the presence of metastases 
was found in 87 patients (46.77%) from the studied group.
Of the patients with PSA values below 10ng/ml (of 72 
patients: 22 with a Gleason score of 5; 30 with a score of 6; 20 
with a score of 7), 37 had no evidence of skeletal metastasis, 
while in 32 single suspected lesions were excluded in CT 
or MRI from being of metastatic origin. In the remaining 
3 patients (4.16%), all of them with Gleason scores of 7, lesions 
were confirmed as metastatic. Of the remaining patients, 
32 of 60 patients (53.33%) with a serum PSA 10.1 – 20.0 ng/ml, 
19 of 21 patients (90.48%) with a serum PSA 20.1–40.0 ng/ml, 
and 33 of 33 patients (100%) with a serum PSA>40 ng/ml had 
positive bone scans for presence of metastases.
Of the 32 patients with positive bone scan results and 
serum PSA level 10.1–20.0 ng/ml, 10 patients had Gleason 
scores of 6; 16 had scores of 7; 3 had scores of 8; and 3 had 
scores of 9.
Based on the above-mentioned data, in the group of 132 
with PSA value <20 ng/ml (35 of them with positive result 
of bone scan), the cutoff value for negative bone scan with 
a confidence interval of 0.95 was established at a PSA value 
below 10 ng/ml (p<0.01). When combining PSA value and 
Gleason score <7 and a negative bone scan with a confidence 
interval of 0.95, the cutoff value was established at a PSA 
value below 13 ng/ml (p<0.01).
As a separate analysis, we evaluated a group of 95 men with 
Gleason scores ≤6. Of this group, 19 (20%) were confirmed 
to have a positive bone scan, 10 (10.53%) of them with a 
PSA level <20 ng/ml. The cutoff value for this group, with a 
confidence interval of 0.95, was established at a PSA value 
below 12 ng/ml (p<0.01).
In the studied group, a correlation was found (r=0.66, 
p<0.05 – fig. 2) between PSA value and the number of 
metastases on the bone scan, as well as a correlation between 
PSA serum and Gleason score in the studied group (r=0.45, 
p<0.05)
Figure 2. Correlation between PSA values and number of metastases on bone scan
Correlations were also found between both PSA value and 
Gleason score and the presence of metastases in particular 
regions (table 2).
Table 2. Correlations between PSA values and Gleason score with 







PSA value 0.31 0.61 0.60 0.70 0.53
Gleason score 0.38 0.61 0.62 0.58 0.47
No correlation was found between pain intensity and both 
PSA value and presence of metastases. Neither did we find 
any correlations between localization of symptoms presented 
by patients and the actual localization of bone metastases 
in bone scan.
DISCUSSION
The foremost aim of our study was to determine whether 
a PSA cutoff of 20 ng/ml, as suggested in the European 
Association of Urology Guidelines, is warranted. Toward 
this end we studied a group of patients suffering from 
newly-diagnosed prostate cancer. Our gathered data from 
performed bone scans support previously published studies 
demonstrating the close relationship between serum PSA 
level and bone scan positivity [6, 11, 12]. In our study, 35 
of 132 patients with a serum PSA <20 ng/ml had a positive 
bone scan. Therefore, for the study group, the cutoff value 
PSA value
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for negative bone scan with a confidence interval of 0.95 was 
established at a PSA value below 10 ng/ml (p<0.01). When 
combining PSA value and Gleason score <7, the negative bone 
scan with a confidence interval of 0.95 was established at a 
PSA value below 13 ng/ml (p<0.01). Based on data from our 
study, we conclude that the European Association of Urology 
guidelines warrant further discussion and trials including 
populations from different regions.
The European Association of Urology guidelines [4, 5] 
recommend staging baseline bone scan scintigraphy in all 
patients with poorly differentiated tumors (Gleason score >7) 
and locally advanced disease (≥cT3) irrespective of the serum 
PSA value. Conversely, in patients with PSA <20 ng/ml, the 
guidelines indicate the need for a staging bone scan only in 
the presence of poorly differentiated prostate cancer and in 
symptomatic patients.
Liu et al. [7] suggested that for patients with PSA ≤10 ng/ml 
or simultaneous PSA ≤50 ng/ml and Gleason score ≤7 and 
clinical stage ≤T2, a bone scan is not necessary. Bantis et al. 
[13] propose even broader criteria, stating that a combination 
of Gleason score >8 and PSA >20 ng/ml is a significant 
predictor of the presence of bone metastases. Others, like 
Briganti et al. and De Nunzio et al. [8, 14] proposed a novel 
classification and regression tree (CART) model, including 
PSA, clinical stage and biopsy Gleason score as covariates. 
Using this model, they stratified patients into low risk (biopsy 
Gleason ≤7, cT1–T3, and PSA <10 ng/ml), intermediate risk 
(biopsy Gleason ≤7, cT2/T3, and PSA >10 ng/ml), and high 
risk of positive bone scan results (biopsy Gleason >7). When 
compared by Briganti and De Nunzio with the European 
Association of Urology guidelines, the CART model was 
significantly more accurate. We neither had access to data 
regarding local advance of the disease, nor could we establish 
it ourselves at the Nuclear Medicine Dept., but apart from 
that our data seem to be in agreement with that of Briganti 
and De Nunzio.
Tanaka et al. [15] presented a large group of patients with 
even lower Gleason scores for which the incidences of bone 
metastases in patients with a prostate-specific antigen level 
of ≤20 ng/ml and Gleason score of ≤6 were reasonably low. 
They conclude that a bone scan is not necessary as a routine 
examination for these patients at the initial staging of prostate 
cancer. In our group the cutoff value with a confidence 
interval of 0.95 was established at a PSA value below 12 ng/ml 
(p<0.01). which is lower than the group studied by Tanaka 
et al. We took into consideration, however, the fact that in our 
group, from suburban and rural areas of Małopolska region, 
probably due to lesser awareness of the disease and lesser 
availability of screening tests, low-grade prostate cancers may 
have gone unrecognized for years, allowing more time for 
the development of bone metastases. Such situation among 
people from suburban and rural areas is not unheard of, and 
have been reported by other authors in case of, for example, 
breast cancer or lung cancer [16,17].
Gleason scores have been suggested by many authors as 
useful predictors of positive bone scans [6,18]. It has been 
stated that the risk of a positive bone scan increases with 
advanced stages and higher grades of prostate cancer. As a 
result of the introduction and wide usage of PSA as a readily-
available tumor marker for prostate cancer, the majority of 
patients now have low serum PSA levels. However, in our 
group, from suburban and rural areas of the Małopolska 
region, many initial PSA results were quite high. Thus, in 
our study, working with a broad range of PSA values at the 
time of diagnosis, we confirmed the existence of a correlation 
between both PSA values and Gleason score with positive 
bone scan results and the number of metastases present.
Pal et al. [19] suggest that a bone scan is of limited value in 
asymptomatic prostate cancer patients with PSA <20 ng/ml, 
which is in agreement with the European Association of 
Urology guidelines. Furthermore, digital rectal examination 
findings, biopsy Gleason score and age are not helpful in 
predicting who might harbor bone metastasis [19]. Analysis 
performed during the course of our study regarding 
symptoms presented by patients and possible correlation 
with presence of bone metastases did not yield any significant 
results. This may have been due to the so-called “community 
background” (rural environment: most men in our study 
were farmers used to hard physical work while suffering pain 
of various degrees from previous traumas and degenerative 
diseases). Thus, we conclude that symptomatology may play 
a lesser role in the diagnostic criteria for application of bone 
scan scintigraphy.
Finally we’d like to stress, that bone scan scintigraphy, 
remains in our opinion, an important tool for staging prostate 
cancer, as previously confirmed, along with Gleason score 
and PSA values [4, 5, 7, 20, 21]. We disagree with some authors 
[22] statements of limited value of bone scan as a first staging 
test. It’s our opinion that there are still regions, in which 
patients may harbor the disease for surprisingly long period 
of time, thus making bone scan scintigraphy a necessity.
CONCLUSIONS
The correlation between PSA value and both presence and 
number of metastases confirms the usefulness of bone scan 
scintigraphy in prostate cancer staging. The cutoff value for 
negative bone scan in studied group with a 95% confidence 
interval was established at PSA = 10 ng/ml, which is a lower 
value than that recommended by the European Association of 
Urology. A Gleason score established through biopsy material 
examination is an independent predictor of metastatic bone 
disease. Pain intensity and localization do not correlate with 
the presence or number of metastases.
LIMITATION OF THE STUDY
Most patients referred for a bone scan by urologists or 
oncologists did not have any information in their medical 
history regarding local advance of the disease. These data 
could provide us with additional information regarding 
the influence of local advance, in addition to Gleason score 
results, on the presence of metastatic bone disease.
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